Head-to-Head showdown: which drug works better for tough Crohn's cases?
NCT ID NCT07149467
Summary
This study directly compares two newer medications, ustekinumab (an injection) and upadacitinib (a pill), for people with Crohn's disease that hasn't responded well to standard treatments. It will enroll 454 adults who previously failed on common biologic drugs like infliximab or adalimumab. The main goal is to see which drug is more effective at getting patients into remission by week 16 and keeping them there.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE AGGRAVATED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.